Advances in knowledge regarding the pathogenesis of psoriasis have allowed the development of a new class of agents known as biologic drugs. Data confirm that T helper (Th)17 and interleukin (IL)-17 signaling has a crucial role in the pathogenesis of the disease. High levels of IL-17 and Th17-related cytokines have been reported in psoriasis, leading to the suggestion of agents targeting IL-17 as a potential therapeutic strategy in psoriasis. Brodalumab is a human monoclonal antibody that targets IL-17 receptor A, blocking the effects of IL-17A, IL-17F, and IL-17E. Data from Phase I and Phase II clinical trials indicate that brodalumab has a favorable safety and tolerability profile, with strong clinical activity, suggesting that it is a potential tool for use in the treatment of moderate-to-severe psoriasis.
Keyphrases
- clinical trial
- phase ii
- monoclonal antibody
- healthcare
- open label
- rheumatoid arthritis
- endothelial cells
- randomized controlled trial
- high intensity
- electronic health record
- atopic dermatitis
- climate change
- early onset
- immune response
- deep learning
- study protocol
- smoking cessation
- double blind
- regulatory t cells
- pluripotent stem cells